Iris Super Speciality Polyclinic Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-12-2024
- Paid Up Capital ₹ 0.10 M
as on 07-12-2024
- Company Age 4 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.63 M
as on 07-12-2024
- Revenue -11.53%
(FY 2022)
- Profit -121.81%
(FY 2022)
- Ebitda -118.31%
(FY 2022)
- Net Worth -227.76%
(FY 2022)
- Total Assets -23.68%
(FY 2022)
About Iris Super Speciality Polyclinic
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.63 M.
Ashok Singh, Sanjeev Dudeja, and Varadan Cetlur serve as directors at the Company.
- CIN/LLPIN
U85100MH2020PTC338934
- Company No.
338934
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Iris Super Speciality Polyclinic?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjeev Dudeja  | Director | 17-Mar-2020 | Current |
| Ashok Singh | Director | 17-Mar-2020 | Current |
| Varadan Cetlur | Director | 17-Mar-2020 | Current |
Financial Performance of Iris Super Speciality Polyclinic.
Iris Super Speciality Polyclinic Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 11.53% decrease. The company also saw a substantial fall in profitability, with a 121.81% decrease in profit. The company's net worth observed a substantial decline by a decrease of 227.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Iris Super Speciality Polyclinic?
In 2022, Iris Super Speciality Polyclinic had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Self Heal Lifesciences Private LimitedActive 10 years 11 monthsAshok Singh and Varadan Cetlur are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 08 Jun 2021 | ₹1.13 M | Open |
Indian Bank Creation Date: 09 Mar 2021 | ₹4.50 M | Open |
How Many Employees Work at Iris Super Speciality Polyclinic?
Iris Super Speciality Polyclinic has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Iris Super Speciality Polyclinic, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Iris Super Speciality Polyclinic's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
